Stablepharma is delighted to welcome Martin Sastre Gallardo to the R&D team at Qube Technology Park in Madrid. As Research Scientist, he will work closely with Lorena Carmona, Senior Scientist, who is leading the RNA-LNP thermostabilisation programme in Spain. Martin joins Stablepharma after working for several years as a Senior Research Scientist at the National […]
Read More
Stablepharma reveals 12 months stability data for our second fridge-free vaccine, SPVX06 for Tetanus. This significant milestone reinforces Stablepharma’s ability to demonstrate the robustness of our platform of reformulated vaccines, including SPVX02 for the prevention of Tetanus diphtheria. In-vivo challenge studies demonstrated that SPVX06 maintains its potency, providing comprehensive protection while effectively stimulating the immune […]
Read More
As Stablepharma continues to expand the teams in both London and Madrid, CEO & Executive Director, Ozgur Tuncer was delighted to announce that Stephanie Maley (of Factotum) has joined the executive team of Stablepharma in the role of Chief People Officer. Stephanie started her career in the finance industry and then moved into HR Consultancy. […]
Read More
Stablepharma is delighted to welcome Dr Kenny Simmen to the Advisory Board, who brings over 30 years pharmaceutical expertise in R&D with a successful track record in drug discovery and external innovation. Dr Simmen will work closely with the science and commercial teams to support further R&D deals and evaluate suitable vaccine candidates that will […]
Read More
click here to read full article
Read More
The United Kingdom is a hub for innovative startups and companies in the realm of impact investing, a variety of investing that seeks to generate both financial return and social or environmental good. Impact investing is fast gaining traction as we move towards a more responsible and sustainable way of doing business. It aligns money […]
Read More
Researchers at University Hospital Southampton (UHS) are working with Stablepharma Ltd to trial vaccines that don’t need to be kept cold. The partners have been awarded a joint grant by Innovate UK to develop a fridge-free vaccine, SPVX02, to prevent tetanus and diphtheria.
Read More
Stablepharma Ltd, the Fridge-free Vaccine Company, has been awarded a second Innovate UK Grant, in partnership with University Hospital Southampton NHS Foundation Trust, as it commences a bridge-funding round in Q4 2023. This joint Innovate UK grant will advance the clinical development of Stablepharma’s lead candidate, SPVX02, a fridge-free vaccine for the prevention of Tetanus […]
Read More